Amir London assumed responsibility as Kamada’s CEO in July 2015.
Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience.
Prior to joining Kamada , Mr. London was the COO of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as home-care solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publicly-traded operations management consulting firm, responsible for the firm’s global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.
Chaime Orlev is serving as our Chief Financial Officer since December 2017. Prior to joining us, he served as Chief Financial Officer and VP Finance and Administration of Bioblast Pharma Ltd (NASDAQ:ORPN) from 2016 to 2017. Prior to that, Mr. Orlev served in various finance positions, in the biotech industry, including VP Finance and Administration of Chiasma Inc. (NASDAQ: CHMA), Chief Financial Officer of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), and Chief Financial Officer of Gammacan Inc. Mr. Orlev also served as VP Finance and Chief Financial Officer of Huntleigh USA Corporation. Mr. Orlev received his M.B.A. from the Leon Recanati Graduate School of Business Administration at the Tel Aviv University and a B.A. in Business Administration from the College of Business in Israel. Mr. Orlev is a Certified Public Accountant under the laws of the state of Israel.
Dr. Ayalon serves as our Vice President of Research & Development since February 2019.
Dr. Ayalon has nearly 20 years of experience in drug discovery and drug development, as a senior biopharmaceuticals executive. Prior to joining Kamada, Dr. Ayalon served as Head of R&D at 89bio Ltd., where she led the overall development strategy of the company and managed all R&D functions, including medical, clinical, pre-clinical, CMC, regulatory, and project management. Previously, Dr. Ayalon was a Project Champion at Teva Pharmaceutical Industries Ltd.. She was also Vice President of Research & Development at Galmed Pharmaceuticals Ltd.. Prior to this, Dr. Ayalon held various R&D positions in biopharmaceutical companies.
Dr. Ayalon holds a Ph.D. in cell biology from Tel-Aviv University, and holds a PostDoc in Molecular Biology of the Cell from the Weizmann Institute of Science.
Eran Nir serves as our VP Operations since November 2016. Mr. Nir has over 14 years of operation management experience in the pharmaceutical and medical industries. His recent roles include management of TEVA’s Pharmaceutical plant in Jerusalem, VP Operations of Emilia Cosmetics and management of a medical equipment plant of Philips Medical Systems. Mr. Nir’s extensive experience spans across the management of large scale FDA and EMA- approved manufacturing facilities, tech-transfer of new products from development to production and the implementation of world-class operational excellence systems.
Mr. Nir has B.SC degree in Industrial Engineering and M.B.A. both from Ben Gurion University.
Yael Brenner has served as our Vice President Quality since March 2015. Mrs. Yael Brenner has experience of more than 20 years in Quality Management, including QA and QC managerial positions in the pharmaceutical industry. Prior to her joining Kamada, her last position in Teva Pharmaceuticals Industries was Senior Director Quality Operations of Teva Kfar Saba Site, managing over 400 workers in QA, QC and RA. Mrs. Brenner holds B.Sc. and M.Sc. degrees in Chemistry from the Technion, Haifa, and in addition Certified Quality Engineer (CQE) from the American and the Israeli and Societies for Quality.
Hanni Neheman serves as Kamada’s Marketing & Sales Vice President since January 2020.
Mrs. Neheman joined Kamada in August 2014 and served as the Head of Business Operations for the Israeli market.
Mrs. Neheman has more than 20 years of experience in different positions in the field of Marketing & Sales in the pharmaceutical industry.
Prior to joining us, she served as a Commercial Manager at Neopharm Israel.
Mrs. Neheman holds a BA degree in Occupational Therapy from Haifa University & Technion, Haifa, and Executive M.B.A from Derby University.
Ariella Raban serves as Kamada’s Vice President, Human Resources since May 2018.
Mrs. Raban joined Kamada in March 2014 and served as Human Resources Manager for Kamada’s manufacturing site. Mrs. Raban has more than a decade of expertise in different positions in the field of HR in the pharmaceutical industry.
Prior to joining us, she served as a Human Resources Manager at Teva Pharmaceuticals.
Mrs. Raban holds a BA degree in Humanities Social Science from Ben-Gurion University.
Orit Pinchuk has served as our Vice President, Regulatory Affairs since October, 2014. Mrs. Pinchuk has experience of more than 20 years in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of Regulatory Affairs and Compliance. Prior to her joining Kamada, her last positions in Teva Pharmaceuticals Industries were Director of Compliance and RA, Operation IL and Sr. Director RA, R&D and Operation IL. She has extensive experience with FDA, EMA and CANADA Health Authorities.
Mrs. Pinchuk holds B.Tech. in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. in Applied Chemistry from Jerusalem Hebrew University.
Ms. Philip serves as our VP, General Counsel and Corporate Secretary since October 2020.
Ms. Philip has been practicing law for more than 15 years, with an experience of over a decade in the BioMed industry. Prior to joining Kamada, she served as VP Legal Affairs and Compliance Officer of OPKO Biologics, a sub of OPKO Health (NASDAQ:OPK), responsible for all company’s legal matters and commercial agreements including IP licensing, R&D collaborations, clinical trials and drug manufacturing contracts. Ms. Philip has vast experience from leading law firms on international biotech M&A deals, joint ventures and commercial transactions. Prior to that, she worked at the Israel Securities Authorities, the Department of Economics and Fiscal Law of the State Attorney, Israel.
Ms. Philip is a member of the Israel Bar Association. She holds an LLB cum laude and a Bachelor’s Degree in Economics from Haifa University; Master cum laude in Law and Economics from Erasmus University in the Netherlands in collaboration with Berkeley University, USA; and an MBA from the Technion-Israel Institute of Technology, Israel.
Ms. Philip also serves as a member of the board of directors of the Israeli Association of Corporate Counsels and head of the ACC BioMed Forum.
Lilach Asher Topilsky is joining as a partner in the FIMI Opportunity Funds, Israel’s largest group of private equity funds, as of December 2019. Until the end of November 2019, Ms. Asher Topilsky serves as the President and CEO of Israel Discount Bank (TASE), one of the leading banking groups in Israel, as the Chairman at IDBNY BANKCORP and as a director at IDB Bank New York, all since February 2014. Ms. Asher Topilsky also served as the Chairman of Mercantile Bank from 2014-2016. Ms. Asher Topilsky is a director at Tel Aviv University and at G1 Ltd. (TASE) (as of December 2019). Prior to joining Israel Discount Bank, Ms. Asher Toplisky served as a member of the management of Bank Hapoalim (TASE) as Deputy Chief Executive Officer and Head of Retail Banking Division (2009-2013) and Head of Strategy and Planning Division (2007-2009). Ms. Asher Topilsky also served as a Strategy Consultant at The Boston Consulting Group (BCG, Chicago 1997-1998) and at Shaldor Strategy Consulting (Israel 1995-1996). Ms. Asher Topilsky holds BA degree in Management and Economics from Tel Aviv University and MBA degree from Kellogg School of Management, Northwestern University.
David Tsur is the Co-founder of Kamada and served as our Chief Executive Officer and on our board of directors since the company’s inception in 1990 until July 2015. Currently he serves as our Deputy Chairman of the Board. Prior to co-founding Kamada, Mr. Tsur was Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur holds a BA degree in Economics and International Relations and an MBA in Business Management from the Hebrew University of Jerusalem.
Leon Recanati has served on our board of directors since May 2005 and has served as Chairman since March 7, 2013. Mr. Recanati currently serves as a board member of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange. He is also a board member of the following private companies: GlenRock Israel Ltd., GlenRock Medical, Shellcase, Gov, Govli Financial Services Ltd., Govli Limited, Microbes Inc., RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Fund and Newbank Ltd. He is currently Chairman and Chief Executive Officer of GlenRock. Previously, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an MBA degree from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.
Amiram Boehm has been a Partner in the FIMI Opportunity Funds, Israel’s largest group of private equity funds, since 2004. Mr. Boehm served as the Managing Partner and Chief Executive Officer of FITE GP (2004), and serves as a director at Gilat Satellite Communications (NASDAQ) , Ham-Let (Israel-Canada) Ltd. (TASE), Hadera Paper Ltd (TASE)., Rekah Pharmaceuticals Ltd (TASE), TAT Technologies Ltd. (NASDAQ, TASE), PCB Technologies Ltd. (TASE) and DIMAR Ltd, DelekSan Ltd. and Galam Ltd. Mr. Boehm previously served as a director of Ormat Technologies Inc. (NYSE, TASE), Scope Metal Trading Ltd. (TASE), Inter Industries, Ltd. (TASE), Global Wire Ltd. (TASE), Telkoor Telecom Ltd. (TASE) and Solbar Industries Ltd. (previously traded on the TASE) and Novolog Ltd (TASE). Prior to joining FIMI, from 1999 until 2004, Mr. Boehm served as Head of Research of Discount Capital Markets, the investment arm of Israel Discount Bank. Mr. Boehm holds a BA degree in Economics and LLB degree from Tel Aviv University and a Joint MBA degree from Northwestern University and Tel Aviv University
Prof. Ari Shamiss is the founder, managing partner and Chairman of the investment committee at Assuta Life Ventures. In the last 4 years he was the CEO of Assuta Medical Centers, the largest private network in Israel consists of 8 hospitals and medical centers with more than $600M in revenues. Prof. Shamiss was the Director of Sheba General Hospital at Tel Hashomer for 10 years.
Prof. Shamiss holds M.D from the Technion Institute and MPA from Harvard University. He is certified in Internal Medicine, Hypertension and Healthcare Management and he is a Professor of Medicine and until recently the Vice Dean at Ben Gurion University School of Medicine with more than 60 published scientific papers.
Prof. Shamiss was the Surgeon General for the Israel Air Force (Col. Ret.) and the Director of its Aeromedical Institute and he is a graduate in excellence of the US Navy Aerospace Medical Institute.
Prof. Shamiss is a board member and advisory at numerous high-tech companies, and is involved in numerous global business projects in healthcare technology and Infrastructure.
Mr. Avraham Berger has served on our board of directors since August 2016. Mr. Berger currently serves as technology investor. Until 2014, Mr. Berger served as a senior partner and chief executive officer of PwC Israel, for more than 20 years. Mr. Berger joined PwC Israel in 1976 and led it from 1991. Mr. Berger has vast experience in mergers and acquisitions and complex public offerings, both in Israel and abroad. Mr. Berger lectures at professional forums and has published several articles in the professional press. Mr. Berger also serves as Chairman of the board of directors of TopAudio Ltd. and serves as director on the board of Weizmann Institute of Science. Mr. Berger holds a Bachelor’s degree in Accounting and Economics awarded from Tel Aviv University and is a certified public accountant in Israel.
Ishay Davidi is the Founder and has served as Chief Executive Officer of the FIMI Opportunity Funds, Israel’s largest group of private equity funds, since 1996. Mr. Davidi currently serves as Chairman of the board of directors of Hadera Paper Ltd. (TASE) and Polyram Plastics Ltd., Dimar Cutting Tools Ltd., and as director at Gilat Satellite Communications Ltd. (NASDAQ), Ham-Let (Israel-Canada) Ltd. (TASE), Rekah Pharmaceuticals Ltd. (TASE), Tadir-Gan Precision materials (TASE), C. Mer Industries Ltd. (TASE), GI Ltd., (TASE), SOS Ltd., DelekSan Ltd., Bet Shemesh Engines Holdings (TASE) and P.C.B Technologies Ltd. Mr. Davidi previously served as the Chairman of the board of directors of Inrom Ltd., Retalix Ltd. (previously traded on NASDAQ and TASE) from August 2008 until January 2010, of Tefron Ltd. (New York Stock Exchange and TASE) and of Tadir-Gan Ltd. (TASE), and as a director at Pharm Up Ltd. (TASE), Ormat Industries Ltd. (previously traded on TASE), Retalix, Tadiran Communications Ltd. (TASE), Lipman Electronic Engineering Ltd. (NASDAQ and TASE), Merhav Ceramic and Building Materials Center Ltd. (TASE), TAT Technologies Ltd. (NASDAQ and TASE), Orian C.M. Ltd. (TASE), Ophir Optronics Ltd., Overseas Commerce Ltd Ltd. (TASE), Scope Metals Group Ltd. (TASE) and Formula Systems Ltd. (NASDAQ and TASE). Prior to establishing FIMI, from 1993 until 1996, Mr. Davidi was the Founder and Chief Executive Officer of Tikvah Fund, a private Israeli investment fund. From 1992 until 1993 Mr. Davidi was the Chief Executive Officer of Zer Science Industries Ltd., a developer of diagnostics equipment for the healthcare industry. Mr. Davidi holds a BSc degree in Industrial and Management Engineering from Tel Aviv University and MBA degree from Bar Ilan University
Jonathan Hahn has served on our board of directors since March 2010. He is currently the President and a director of Tuteur. Previously, Mr. Hahn held a business development position in Forest Laboratories, Inc., based in New York. Mr. Hahn holds a BA degree from San Andrés University and an MBA degree from New York University — Stern School of Business, with specializations in Finance and Entrepreneurship.
Karnit Goldwasser serves as an independent consultant and environmental engineer for various agencies and organizations. Ms. Goldwasser is a director at Orian DB Schenker (since September 2017), Delek San Recycling Ltd. (since December 2016) and ELA Recycling Corporation (since April 2015). Ms. Goldwasser served as a director at the government-owned Environmental Services Company Ltd., as chair of the Safety Committee (2010-2016), and as a member of the Tel Aviv-Jaffa City Council, holding the environmental portfolio (2013-2016). Ms. Goldwasser also served as a director in several Tel Aviv-Jaffa municipality corporations: Dan Municipal Sanitation Association, as chair of the audit committee; Tel Aviv-Jaffa Economic Development Authority; and Ganei Yehoshua Co. Ltd. Ms. Goldwasser holds a B.Sc. degree in Environmental Engineering, focusing on chemistry, mathematics and environmental engineering, and M.Sc. degree in Civil Engineering, specializing in Hydrodynamics and Water Resources, both from the Technion – Israel Institute of Technology, and MA degree in Public Policy and Administration from the Lauder School of Government Diplomacy and Strategy, IDC Herzliya. Ms. Goldwasser also completed the Directors Program at LAHAV, School of Management, Tel Aviv University.